TNF-alpha inhibitors
ApprovedSmall molecule
TNF-alpha inhibitors is one of 69 small molecule programs targeting Rheumatoid Arthritis. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1TNF-alpha inhibitors
MMedical University of Vienna
Approved
Rituxan
RochePreclinical
Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Cimzia
UCBPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Ilaris
NovartisPreclinical
Actos
TakedaPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Papilloma1 trial
Rheumatoid Arthritis1 trial
Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes
Terminated·—·Phase 4·NCT02236481·41 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TNF-alpha inhibitors. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMedical University of Vienna